AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 111 min read$ROIV

Fitzgerald Meghan sold $798K of ROIV

Fitzgerald Meghan sold 20,000 shares of Roivant Sciences Ltd. (ROIV) at $39.90 ($0.80M total) on 2026-09-08 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Fitzgerald Meghan
Published Sep 11, 2026, 1:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 11, 2026, 1:25 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$ROIV
Neutral
medium confidence
Mentioned
$ROIV
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ROIVNeutralLow
01

Why it matters

The sale is a routine liquidity event with limited market impact.

02

Market read

Routine insider sale; low trading relevance.

03

What to watch

Possible upcoming corporate actions not disclosed.

Relevance 4/10Novelty 4/10Timing: filed after market on Sep 10, 2026

Background

Form 4 filings disclose insider transactions; director sales are monitored for signals.

Company-level read

Ticker impact

$ROIVNeutralMedium confidence
Context

Director Meghan Fitzgerald sold 20,000 shares for $798,000 via a 10b5-1 plan, reducing her stake to 42,963 shares.

Expected impact

Limited short-term pressure; price likely unchanged.

Evidence & confidence

Director-level sale under $1M is routine; market impact typically minimal.

Market effects

Sector

None significant for biotech sector.

Regional

No regional effect.

Global

Minimal global relevance.

Counterpoint

What could challenge this read

Potential undervaluation if insider is reducing exposure ahead of upcoming news.

Key entities

  • Director
    Meghan Fitzgerald

    Director of Roivant Sciences Ltd.

  • Company
    Roivant Sciences Ltd.

    Biotech company listed on NYSE under ROIV.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ROIV insider trading history →

Related articles

OCT 5
$ROIVMedAI 8/10

Transcript: Roivant Sciences Q1 2027 Earnings Conference Call - Roivant Sciences (NASDAQ:ROIV)

Roivant Sciences (ROIV) reported Q1 2026 results, highlighting a quiet quarter with progress in its pipeline, particularly brepocitinib's Phase 3 study. The company received a $950M settlement from Moderna and has ongoing litigation against Pfizer and BioNTech. Financially, ROIV reported $200M in R&D expenses, $100M in non-GAAP G&A expenses, and a cash position of nearly $4B. Management expects a busy second half with brepocitinib's launch and other pipeline updates.

benzinga.com3 min
OCT 5
Med

Roivant, the ‘inveterate drug hunters’, enters commercial era with Lisraya

Roivant Sciences, a biopharma company with a unique hub-and-spoke model, is transitioning into a commercial phase with the launch of Lisraya, an oral TYK2/JAK inhibitor for dermatomyositis. CEO Matt Gline aims to differentiate the company with a commercial portfolio, including Lisraya, Pulmovant’s mosliciguat, and Immunovant’s IMVT-1402. Leerink Partners estimates Lisraya could generate $7.9 billion in sales by 2035, with mosliciguat's expectations raised to $9.8 billion.

biospace.com3 min
SEP 24
$ROIVMedAI 8/10

Roivant’s Lung Drug Clears Phase 2 Test: Is Another Major Pipeline Asset Emerging?

Roivant Sciences (ROIV) shares rose 17% after reporting positive Phase 2 results for mosliciguat, its experimental treatment for pulmonary hypertension. The drug met primary and secondary endpoints, reducing pulmonary vascular resistance by 56.3% and improving six-minute walk distance. J.P. Morgan estimates peak sales of $1.5B, though this is an analyst forecast. Roivant is now advancing to Phase 3 trials.

insidermonkey.com3 min